| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Other Original Articles |
INSERM, U-361, Maternité Port Royal Hôpital Cochin, Université René Descartes (C.M., G.T., E.D., D.C., F.F., M.-J.L.), 75014 Paris, France; and Division of Reproductive Biology, Stanford University School of Medicine (C.M.), Stanford, California 94305-5317
Address all correspondence and requests for reprints to: Dr. Marie-Josèphe Leroy, INSERM, U-361, Pavillon Baudelocque, 123 boulevard Port Royal, 75014 Paris, France. E-mail: leroy-zamia{at}u361.cochin.inserm.fr
Abstract
Elevation of cAMP content resulting from stimulation of the receptor-adenylyl cyclase complex is involved in maintaining the quiescence of the human myometrium during pregnancy. The magnitude of this elevation is critically influenced by the rate of cAMP hydrolysis by phosphodiesterase (PDE) isoenzymes. In the present study we report that in term myometrium, enhanced cAMP-specific PDE4 activity takes part in the heterologous desensitization to the ß-mimetic, salbutamol. Indeed, pretreatment with a PDE4-selective inhibitor potentiates the relaxant effect of salbutamol on myometrial strips of women at term. Furthermore, the reduced relaxant effect of salbutamol after long-term treatment of myometrial strips with PGE2, a potent myometrial effector, can be reversed by PDE4 inhibition. Using a model of cultured myometrial cells, we also demonstrated that PGE2 is able to up-regulate PDE4 activity, at least through the induction of synthesis of PDE4B and PDE4D short forms, which, in turn, dampen the cAMP accumulation provoked by the stimulation of adenylyl cyclase. Such data suggest that in late pregnancy endogenous PGE2 might up-regulate PDE4 activity and lessen the responsiveness of myometrium to ß-mimetic activation. Accordingly, coapplication of a selective PDE4 inhibitor might greatly improve the usefulness of ß-mimetic in tocolysis.
This article has been cited by other articles:
![]() |
R. Herve, T. Schmitz, D. Evain-Brion, D. Cabrol, M.-J. Leroy, and C. Mehats The PDE4 Inhibitor Rolipram Prevents NF-{kappa}B Binding Activity and Proinflammatory Cytokine Release in Human Chorionic Cells J. Immunol., August 1, 2008; 181(3): 2196 - 2202. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hu, G. Nino, J. S. Grunstein, S. Fatma, and M. M. Grunstein Prolonged heterologous {beta}2-adrenoceptor desensitization promotes proasthmatic airway smooth muscle function via PKA/ERK1/2-mediated phosphodiesterase-4 induction Am J Physiol Lung Cell Mol Physiol, June 1, 2008; 294(6): L1055 - L1067. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Giembycz and R. Newton Beyond the dogma: novel {beta}2-adrenoceptor signalling in the airways. Eur. Respir. J., June 1, 2006; 27(6): 1286 - 1306. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Breuiller-Fouche and G. Germain Gene and protein expression in the myometrium in pregnancy and labor. Reproduction, May 1, 2006; 131(5): 837 - 850. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. G. Tilley and D. H. Maurice Vascular Smooth Muscle Cell Phenotype-Dependent Phosphodiesterase 4D Short Form Expression: Role of Differential Histone Acetylation on cAMP-Regulated Function Mol. Pharmacol., September 1, 2005; 68(3): 596 - 605. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Charpigny, M.-J. Leroy, M. Breuiller-Fouche, Z. Tanfin, S. Mhaouty-Kodja, Ph. Robin, D. Leiber, J. Cohen-Tannoudji, D. Cabrol, C. Barberis, et al. A Functional Genomic Study to Identify Differential Gene Expression in the Preterm and Term Human Myometrium Biol Reprod, June 1, 2003; 68(6): 2289 - 2296. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Oger, C. Mehats, E. Dallot, F. Ferre, and M.-J. Leroy Interleukin-1{beta} Induces Phosphodiesterase 4B2 Expression in Human Myometrial Cells through a Prostaglandin E2- and Cyclic Adenosine 3',5'-Monophosphate-Dependent Pathway J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5524 - 5531. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. G. Tilley and D. H. Maurice Vascular Smooth Muscle Cell Phosphodiesterase (PDE) 3 and PDE4 Activities and Levels are Regulated by Cyclic AMP in Vivo Mol. Pharmacol., September 1, 2002; 62(3): 497 - 506. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |